3
3
1
1
2
2
1
1
2
2
2
2
1
1
1
1
1
1
1
1
2020
2010
Company (30)University (14)Research Institution (2)Hospital (1)
1 - 10 of 30
Sort by
Patent
Publication NumberUS 20200061123Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-10-17Publication Date2020-02-27
A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity sugg…
Research Grant
Project Number1R42NS112070-01Funding AgencyNational Institutes of HealthEffective Date2019-09-15Expiration Date2020-08-31Funding Amount$843,689
ABSTRACT/SUMMARY In previous studies we identified novel non-hematopoietic umbilical cord blood stem cells (nh- UCBSCs) that could be expanded to high passages and exhibit restorative properties following ischemic brain injury repair. We found that the high passaged cells were equivalent, if not even better, than the low passaged nh-UCBSCs. This finding suggests that these cells can serve as a source of highly expandable cells that can be manufactured under controlled conditions for potential…
Patent
Publication NumberUS 20180042968Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-10-23Publication Date2018-02-15
The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
Patent
Publication NumberUS 9795637Filing StatusIssued PatentAvailabilityLicensableFiling Date2012-10-09Publication Date2017-10-24
The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
Patent
Publication NumberUS 9044431Filing StatusIssued PatentAvailabilityLicensableFiling Date2011-05-13Publication Date2015-06-02
A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phen…
Clinical Trial
Clinical Trial IDNCT02433509Start Date2015-05-01Completion Date0031-11-29PhasePhase 1Study TypeInterventionalStatusRecruiting
The objective of the study is to determine the safely of Human Umbilical Cord Blood mononuclear cells by Intravenous injection in acute ischemic stroke patients.
Patent
Publication NumberUS 8765119Filing StatusIssued PatentAvailabilityLicensableFiling Date2005-05-06Publication Date2014-07-01
A method of treating a patient with a neurodegenerative disease, such as ALS, using progenitor cells isolated from human umbilical cord blood. Non-invasive transplantation of aldehyde dehydrogenase (ALDH+) expressing progenitor cells provides cell replacement and protection of motor neurons.
Research Grant
Project Number5R41NS080329-02Funding AgencyNational Institutes of HealthEffective Date2014-03-01Expiration Date2016-02-29Funding Amount$211,473
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. However, tPA does not reduce lesion volume nor improve functional outcome, but increases the inciden…
Research Grant
Project Number1R41NS080329-01A1Funding AgencyNational Institutes of HealthEffective Date2013-03-01Expiration Date2014-02-28Funding Amount$211,473
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. However, tPA does not reduce lesion volume nor improve functional outcome, but increases the inciden…
Patent
Publication NumberUS 8309352Filing StatusIssued PatentAvailabilityLicensableFiling Date2006-11-09Publication Date2012-11-13
The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
We found 30 documents that match your Search
Research Grants: 16
Patents: 13
Clinical Trials: 1

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in